ADPKDに伴う高血圧治療におけるCCBの安全性に関する研究

基本情報

NCT ID

NCT00541853

ステータス

不明

試験のフェーズ

第4相

試験タイプ

介入

目標被験者数

150

治験依頼者名

Kyorin University

概要

This study examines the safety and efficacy of calcium channel blocker (CCB) in the treatment of hypertension of Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients. Angiotensin receptor blocker (ARB) was shown to have kidney protecting effects in patients with renal diseases including ADPKD, glomerulonephritis and diabetic nephropathy. In case whose blood pressure is not normalized by ARB alone, CCB is selected additionally. Recent research suggests genetic calcium channel disorder is responsible for the progression of ADPKD. It is not examined clinically if CCB treatment has any harmful effect to patients with ADPKD. This study examines the safety of Cilnidipine (CCB) in the ADPKD patients whose blood pressure is not controlled under 130/85 mmHg by Candesartan (ARB) alone.

対象疾患

介入

依頼者（Sponsor）

実施施設 (6)